FortressBiotech優先A FBIOP 深滬

已收盤 02-06 16:00:00 美东时间

11.99

+0.190

+1.61%

華盛通

立即下載

最高11.99
今開11.92
成交量 6497股
最低 11.7014
昨收 11.80
總市值 4109.14万
52周最高 12.98
市盈率 ^靜 --
換手率 0.19%
52周最低 4.72
委比 -70.80%
總股本 342.71万
歷史最高 20.5506
量比 0.41
振幅 2.45%
歷史最低 -1.5766
每手 1
風險率 1.70%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has approved ZYCUBO®

01-13 20:51
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics announced the FDA approval of ZYCUBO (copper histidinate) for Menkes disease, the first FDA-approved treatment for this rare pediatric condition. Sentynl Therapeutics assumed responsibility for ZYCUBO’s development and commercialization, transferring a Rare Pediatric Disease Priority Review Voucher (PRV) to Cyprium and offering up to $129 million in milestones. ZYCUBO significantly improves survival in Me...

01-13 12:45
Fortress Biotech Amends Credit Agreement with Oaktree

Fortress Biotech ( ($FBIO) ) has shared an announcement. On December 12, 2025, ...

2025-12-16 06:45
Fortress Biotech Q3 EPS $0.11 Beats $(0.42) Estimate, Sales $17.631M Miss $21.018M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.42) by 126.19 percent. This is a 114.47 percent increase over losses of $(0.76) per share

2025-11-14 21:43
Fortress Biotech Q3 Earnings Preview

Fortress Biotech (FBIO) is scheduled to announce Q3 earnings results on Wednesday, November 12th, after market close. The consensus EPS Estimate is -$0.63 and the consensus Revenue Estimate is $21.02M...

2025-11-12 06:35
Fortress Biotech Receives FDA Response on CUTX-101

Fortress Biotech ( ($FBIO) ) has shared an announcement. On October 1, 2025, Fo...

2025-10-01 21:19
Fortress Biotech plunges as FDA rejects rare disease drug

Fortress Biotech (NASDAQ:FBIO) fell ~31% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve CUTX-101, a treatment developed by the company and its Indi...

2025-10-01 20:59
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...

2025-09-05 05:13
Fortress Biotech shares are trading higher after the company reported better-than-expected Q2 sales results.

Fortress Biotech shares are trading higher after the company reported better-th...

2025-08-16 00:36
Fortress Biotech Q2 EPS $0.45 Beats $(0.36) Estimate, Sales $16.413M Beat $14.534M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $(0.36) by 225 percent. This is a 161.64 percent increase over losses of $(0.73) per share from

2025-08-15 04:27

派息除權日	每股總股息	派息日期
2024-06-14	0.20	2024-06-30
2024-05-14	0.20	2024-05-31
2024-04-12	0.20	2024-04-30
2024-03-14	0.20	2024-03-31
2024-02-14	0.20	2024-02-29
2024-01-11	0.20	2024-01-31
2023-12-14	0.20	2023-12-31
2023-11-14	0.20	2023-11-30
2023-10-12	0.20	2023-10-31
2023-09-14	0.20	2023-09-30
2023-08-14	0.20	2023-08-31
2023-07-13	0.20	2023-07-31
2023-06-14	0.20	2023-06-30
2023-05-12	0.20	2023-05-31
2023-04-13	0.20	2023-04-30
2023-03-14	0.20	2023-03-31
2023-02-14	0.20	2023-02-28
2023-01-12	0.20	2023-01-31
2022-12-14	0.20	2022-12-31
2022-11-14	0.20	2022-11-30
2022-10-13	0.20	2022-10-31
2022-09-14	0.20	2022-09-30
2022-08-12	0.20	2022-08-31
2022-07-14	0.20	2022-07-31
2022-06-14	0.20	2022-06-30
2022-05-12	0.20	2022-05-31
2022-04-13	0.20	2022-04-30
2022-03-14	0.20	2022-03-31
2022-02-14	0.20	2022-02-28
2022-01-13	0.20	2022-01-31
2021-12-14	0.20	2021-12-31
2021-11-12	0.20	2021-11-30
2021-10-14	0.20	2021-10-30
2021-09-14	0.20	2021-09-30
2021-08-12	0.20	2021-08-30
2021-07-14	0.20	2021-07-30
2021-06-14	0.20	2021-06-30
2021-05-13	0.20	2021-05-30
2021-04-14	0.20	2021-04-30
2021-03-12	0.20	2021-03-31
2021-02-11	0.20	2021-02-28
2021-01-14	0.20	2021-01-31
2020-12-14	0.20	2020-12-31
2020-11-12	0.20	2020-11-30
2020-10-14	0.20	2020-10-31
2020-09-14	0.20	2020-09-30
2020-08-20	0.20	2020-08-31
2020-07-17	0.20	2020-07-31
2020-06-12	0.59	2020-06-30
2020-03-13	0.59	2020-03-31
2019-12-12	0.59	2019-12-31
2019-09-12	0.59	2019-09-30
2019-06-13	0.59	2019-07-01
2019-03-14	0.59	2019-03-31
2018-12-13	0.59	2018-12-31
2018-09-13	0.59	2018-09-30
2018-06-14	0.59	2018-06-30
2018-03-14	0.59	2018-03-30

公司名稱	Fortress Biotech, Inc.
行業分類	Pharmaceuticals: Major
業務描述	Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

FortressBiotech優先A FBIOP 深 滬

11.99

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

FortressBiotech優先A FBIOP 深滬